000157452 001__ 157452
000157452 005__ 20240229123138.0
000157452 0247_ $$2doi$$a10.1186/s12885-020-07219-z
000157452 0247_ $$2pmid$$apmid:32770972
000157452 0247_ $$2pmc$$apmc:PMC7414549
000157452 0247_ $$2altmetric$$aaltmetric:88562896
000157452 037__ $$aDKFZ-2020-01631
000157452 041__ $$aeng
000157452 082__ $$a610
000157452 1001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b0$$eFirst author$$udkfz
000157452 245__ $$aProtocol of the VICTORIA study: personalized vitamin D supplementation for reducing or preventing fatigue and enhancing quality of life of patients with colorectal tumor - randomized intervention trial.
000157452 260__ $$aHeidelberg$$bSpringer$$c2020
000157452 3367_ $$2DRIVER$$aarticle
000157452 3367_ $$2DataCite$$aOutput Types/Journal article
000157452 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1600154584_28878$$xReview Article
000157452 3367_ $$2BibTeX$$aARTICLE
000157452 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157452 3367_ $$00$$2EndNote$$aJournal Article
000157452 500__ $$a#EA:C070#LA:C070
000157452 520__ $$aCancer-related fatigue represents one major cause of reduced quality of life in cancer patients and can seriously affect the physical, emotional, and cognitive functioning impeding coping with the disease. Options for effective treatment of cancer-related fatigue are limited, consisting only of non-pharmacologic interventions like physical activity, psychosocial, and mind-body interventions. Recent evidence suggests that vitamin D3 supplementation might alleviate cancer-related fatigue. However, confirmation in a randomized controlled trial is needed.In this multicenter, randomized, double-blind, placebo-controlled trial, 456 colorectal cancer (CRC) patients aged 18 years and older are being recruited in three German rehabilitation clinics. Study inclusion requires hospitalization of at least 3 weeks at such a clinic, a diagnosis of non-metastatic CRC (stage I-III), surgical removal of the tumor within the past 9 months, and season-adapted vitamin D insufficiency or deficiency. Eligible patients are randomly assigned to a personalized regimen of vitamin D3 or placebo for 12 weeks. In the intervention group, a loading dose of 20,000 or 40,000 IU vitamin D3 will be administered daily during the first 11 days, followed by a maintenance dose of 2000 IU daily. Patients will complete questionnaires for secondary outcomes (fatigue subdomains, quality of life and subdomains, depression, functional well-being, and infection frequency). Blood and urine samples will be collected for analyses of safety parameters (hypervitaminosis D, hypercalcemia, hypercalciuria, and renal impairment) and efficacy biomarkers (25-hydroxyvitamin D, HbA1c, white blood cell count, leukocyte subtype counts, serum C-reactive protein, uric acid, creatinine, triglycerides, total, low- and high-density lipoprotein cholesterol).This trial tests whether a personalized vitamin D3 dosing regimen reduces or prevents fatigue among non-metastatic CRC patients by treating the underlying vitamin D deficiency/insufficiency. If efficacy can be confirmed, personalized vitamin D3 supplementation could be used as a tertiary prevention measure in addition to non-pharmacological treatments of cancer-related fatigue in CRC patients. We expect to detect an effect of vitamin D3 supplementation on secondary outcomes like quality of life, depression, functional well-being, infections, inflammatory biomarkers, diabetes mellitus, and dyslipidemia.European Clinical Trials Database: EudraCT-No: 2019-000502-30, January 21, 2019; German Clinical Trials Register (DRKS): DRKS00019907 , April 30, 2019.
000157452 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000157452 588__ $$aDataset connected to CrossRef, PubMed,
000157452 7001_ $$0P:(DE-He78)a1d1b323625dcfa155b477a646cbda52$$aKuznia, Sabine$$b1$$udkfz
000157452 7001_ $$0P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57$$aLaetsch, Dana Clarissa$$b2$$udkfz
000157452 7001_ $$aCzock, David$$b3
000157452 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b4$$udkfz
000157452 7001_ $$aCaspari, Reiner$$b5
000157452 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b6$$eLast author$$udkfz
000157452 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-020-07219-z$$gVol. 20, no. 1, p. 739$$n1$$p739$$tBMC cancer$$v20$$x1471-2407$$y2020
000157452 909CO $$ooai:inrepo02.dkfz.de:157452$$pVDB
000157452 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000157452 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1d1b323625dcfa155b477a646cbda52$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000157452 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000157452 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000157452 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000157452 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000157452 9141_ $$y2020
000157452 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC CANCER : 2018$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2019-12-20
000157452 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2019-12-20
000157452 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2019-12-20
000157452 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2019-12-20
000157452 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000157452 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000157452 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000157452 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000157452 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x2
000157452 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000157452 980__ $$ajournal
000157452 980__ $$aVDB
000157452 980__ $$aI:(DE-He78)C070-20160331
000157452 980__ $$aI:(DE-He78)C060-20160331
000157452 980__ $$aI:(DE-He78)C120-20160331
000157452 980__ $$aI:(DE-He78)HD01-20160331
000157452 980__ $$aUNRESTRICTED